Hematology-Oncology
Molecular Profiling Refines Relapse Risk After Allogeneic Transplant in First-Remission Acute Myeloid Leukemia
By MedXY|May 11, 2026
A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.
